Multimodal analgesia in patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE): a randomized comparative study
10.3760/cma.j.issn.1007-8118.2017.06.005
- VernacularTitle:多模式镇痛在肝癌患者肝动脉化疗栓塞术中的应用
- Author:
Yuefeng RAO
;
Luping ZHAO
;
Rongrong WANG
;
Xuejiao GUO
;
Tanyang ZHOU
;
Liming CHEN
;
Sheng YAN
;
Junhui SUN
;
Xiaoyang LU
;
Zhiying FENG
- Keywords:
Hepatocellular carcinoma;
Transarterial chemoembolization (TACE);
Multimodal analgesia
- From:
Chinese Journal of Hepatobiliary Surgery
2017;23(6):375-379
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study multimodal analgesia in patients who underwent transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).Methods 60 patients who underwent TACE for HCC from Aug.2016 to Nov.2016 were randomized into two groups:the multimodal analgesia group and the control group.The pain scores of these two groups of patient during the procedure and at different posttreatment time points,and the rates of adverse effect and pharmacoeconomic differences were recorded.Results When compared to the control group,the pain scores at 0 h,2 h,4 h,6 h,12 h after treatment in the multimodal analgesia group were significantly lower (P ＜ 0.05),and the satisfactory scores for the patients were significantly improved (96.6％ vs.66.7％).The multimodal group of patients also had significandy lower adverse effect rates of nausea and vomiting,and it was more cost-effective.Conclusions Patients who required multimodal analgesia had better pain relieve,patient satisfaction and less adverse reactions after TACE than patients in the control group.Multimodal analgesia was a safe,effective and economic way to control TACE pain and it was worth recommended in clinical practice.
